Comparing the current results to its competitors, Annexon Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 10.39 %, recorded in the same quarter.
Annexon Inc 's Comment on Competition and Industry Peers
The company operates within the pharmaceutical, biopharmaceutical, and biotechnology industries, which are marked by rapid technological advancements and strong competition. Its competitors include pharmaceutical, biopharmaceutical, and biotechnology firms, academic institutions, governmental agencies, and both public and private research organizations. These competitors may possess greater financial resources, established market presence, and expertise in research and development, manufacturing, clinical testing, regulatory approvals, reimbursement, and marketing. Competition also extends to recruiting qualified personnel, establishing clinical trial sites, patient registration, and acquiring complementary technologies. Additionally, smaller or early-stage companies can be significant competitors, particularly through collaborations with larger companies.
April 8, 2025
: This article summarises pivotal Phase 3 data presented by Annexon at the American Academy of Neurology’s 2025 Annual Meeting, reinforcing the potential of Tanruprubart (formerly ANX005) as a targeted therapy for Guillain-Barré Syndrome (GBS). Insights into the clinical benefits observed across all stages of GBS bolster the therapeutic landscape for this challenging condition. We also explore market sentiments surrounding Annexon amidst discussions of financial sustainability and strategic innovations aimed at enhancing patient education.Guillain-Barré Syndrome (GBS) remains a medical enigma characterised by acute, immune-mediated peripheral nerve damage, leading to varying degrees of muscle weakness a...
October 15, 2024
In a significant development for ophthalmology and the treatment of dry age-related macular degeneration (AMD), Annexon has announced plans to present new findings from its Phase 2 clinical trial of ANX007 at the upcoming American Academy of Ophthalmology (AAO) 2024 meeting. This trial, known as ARCHER, focused on the efficacy of ANX007 in patients with less advanced geographic atrophy (GA), a condition that can lead to vision loss and severely impact quality of life. The Promise of ANX007ANX007, a monoclonal antibody, aims to target and inhibit the complement component C1q, which is part of the immune system involved in the pathogenesis of GA. The early data from the ARCHER study have demonstrated promising...
January 8, 2024
In a recent breakthrough, Annexon, a renowned biopharmaceutical company, has meticulously delineated its priorities for the year 2024, pivoting towards the milestone of late-stage clinical trials across its upstream complement portfolio. The portfolio comprises an array of groundbreaking treatments for autoimmune, ophthalmic, and neurodegenerative diseases. This revolutionary development brings immense hope for the medical fraternity and patients grappling with these severe health conditions.Indefeasibly leading the charge, the company s ANX005 phase 3 clinical program is on course to deliver pivotal data in the first half of 2024. This study primarily targets Guillain-Barré Syndrome (GBS), a rare neurologi...
Nektar Therapeutics operates under a business model focused on developing and commercializing innovative medicines. The company's approach involves utilizing its proprietary technology platforms to create novel therapeutic candidates and establish partnerships with pharmaceutical and biotechnology firms for clinical development and commercialization. Nektar Therapeutics aims to bring transformative therapies to market that address significant unmet medical needs.
Nexien Biopharma Inc operates as a biotechnology company focused on the development and commercialization of innovative therapies for various medical conditions. They aim to use their expertise in biopharmaceutical research to bring novel treatments to market, improving patient outcomes and meeting unmet medical needs.
Sources:
Annexon Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Annexon Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
